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Abstract
Antigenic variation in the globular domain of influenza A virus (IAV) hemagglutinin (HA) precludes effective immunity to this
major human pathogen. Although the HA stem is highly conserved between influenza virus strains, HA stem-reactive
antibodies (StRAbs) were long considered biologically inert. It is now clear, however, that StRAbs reduce viral replication in
animal models and protect against pathogenicity and death, supporting the potential of HA stem-based immunogens as
drift-resistant vaccines. Optimally designing StRAb-inducing immunogens and understanding StRAb effector functions
require thorough comprehension of HA stem structure and antigenicity. Here, we study the biogenesis of HA stem epitopes
recognized in cells infected with various drifted IAV H1N1 strains using mouse and human StRAbs. Using a novel
immunofluorescence (IF)-based assay, we find that human StRAbs bind monomeric HA in the endoplasmic reticulum (ER)
and trimerized HA in the Golgi complex (GC) with similar high avidity, potentially good news for producing effective
monomeric HA stem immunogens. Though HA stem epitopes are nestled among several N-linked oligosaccharides,
glycosylation is not required for full antigenicity. Rather, as N-linked glycans increase in size during intracellular transport of
HA through the GC, StRAb binding becomes temperature-sensitive, binding poorly to HA at 4uC and well at 37uC. A de novo
designed, 65-residue protein binds the mature HA stem independently of temperature, consistent with a lack of N-linked
oligosaccharide steric hindrance due to its small size. Likewise, StRAbs bind recombinant HA carrying simple N-linked
glycans in a temperature-independent manner. Chemical cross-linking experiments show that N-linked oligosaccharides
likely influence StRAb binding by direct local effects rather than by globally modifying the conformational flexibility of HA.
Our findings indicate that StRAb binding to HA is precarious, raising the possibility that sufficient immune pressure on the
HA stem region could select for viral escape mutants with increased steric hindrance from N-linked glycans.
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Introduction
IAV is responsible for considerable human morbidity and
mortality, with enormous attendant economic costs. Current
vaccines are at best effective only for a few years due to the
evolution of human IAV strains that escape vaccine- or infection-
induced immunity. The most relevant immune escape occurs in
the HA, a homotrimeric viral surface type I integral membrane
glycoprotein. HA initiates IAV infection by attaching virus to host
cell sialic acid receptors and fusing viral and host membranes in
acidifying endosomes. Abs to HA neutralize infectivity by blocking
virus attachment or acid-triggered conformational changes on HA
that mediate host-viral membranes fusion [1].
HA consists of a globular ‘‘head’’ domain containing the sialic
binding site topping a stem containing the fusion domain [2]. Most
neutralizing anti-HA Abs induced in experimental animals and
humans are specific for the HA globular domain, which correlates
well with the focus of the immune driven evolution on residues
within this domain, particularly in the major antigenic regions
(termed Sa, Sb, Ca1, Ca2, and Cb in H1 subtype HAs).
Monoclonal Abs (mAbs) of defined fine-specificity have proven
to be invaluable reagents for studying not only HA antigenicity [3–
6] but also HA structure [7], function, and biogenesis in
biochemical and immunohistochemical studies [8–10].
HA folding begins co-translationally [11,12], and HA mono-
mers are substantially folded in the ER [10]. HA trimerization
occurs either in the ER [10,13] or in a post-ER compartment [9]
depending on the IAV strain studied. H1 HA oligomerization
generates epitopes present in both the antigenic sites that bridge
adjacent HA monomers (Ca1 and Ca2) as well as epitopes in the
Sa and Cb sites [14]. Remarkably, many trimerization-dependent
epitopes on HA persist after oligomer dissociation and fragmen-
tation, demonstrating that complete folding of HA monomers
requires trimerization [14].
Relative to the HA head, the HA stem exhibits little evolution
among human IAV strains. This, and the failure to detect efficient
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neutralizing, HA stem-specific mAbs or polyclonal Abs (pAbs)
[15,16], led to a consensus that the stem region of HA is a poor
vaccine target. Unfortunately, dogma-challenging findings from
Okuno and colleagues clearly demonstrating the potential of
StRAbs as broadly neutralizing agents [17,18] were viewed as
curiosities. All of this changed, however, when the isolation of
mAbs from circulating B cells revealed that StRAbs are common
in humans [19–24], and can be experimentally induced without
difficulty in animals following a variety of immunization protocols
[25–27].
These findings support the potential of HA stem-based
immunogens as drift-resistant vaccines. Here, we examine the
biogenesis of the principal site recognized by StRAbs. Our findings
have important implications for immunogen design and possible
viral escape from protective StRAbs.
Results
Biogenesis of HA Stem Epitopes Recognized by Mouse
and Human mAbs
We examined the biogenesis of HA stem epitopes by 2 min
radiolabeling IAV A/Puerto Rico/8/34 (PR8)-infected MDCK
cells with [35S]-Met and chasing for up to 20 min at 37uC. We
then recovered HA from non-ionic detergent (Triton X-100)
lysates using mouse (C179 [18]) or human (1F02 [23]) StRAbs. We
analyzed HA by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) under non-reducing conditions.
Due to partial disulfide exchange post-lysis [14], oligomerized
HA migrates as a mixture of denatured monomers, dimers, and
trimers under these conditions (Fig. 1A). These StRAbs, like the
HA monomer-specific, anti-HA head mAb Y8-10C2 [9,14], bind
to HA from the earliest chase time point, indicating their binding
to monomeric HA (Fig. 1A). Moreover, C179 and 1F02 clearly
recognize oligomeric forms of HA, as seen for the HA trimer-
specific, anti-HA head mAb H17-L2 [9,14] (Fig. 1A). Importantly,
we observed similar reactivity to HA using other StRAbs that bind
HAs from group 1 IAV, such as human 2A06, 2G02, and 3A01
[28] (Fig. S1). 2G02 is particularly interesting since it compre-
hensively neutralizes group 1 and group 2 IAV [28,29], which
suggests its probably binding to a different sight on the HA stem. It
is worth mentioning, however, that StRAbs that bind to HA
epitopes in a different manner than C179/CR6261 [30] might
well behave differently. We also obtained similar results using a
panel of drifted human IAV H1N1 strains, including the
pandemic H1N1 2009 virus (Fig. S2).
To distinguish recognition of monomeric vs. trimerized HA, we
used the HA monomer-specific mAb Y8-10C2 or the HA trimer-
specific mAb H17-L2 to completely deplete cell lysates of HA
monomers or trimers, respectively, prior to exposing lysates to
either C179 or 1F02 [14]. This confirmed that C179 and 1F02
bind well to HA trimers, and that 1F02 also robustly binds HA
monomers (Fig. 1A). C179 also clearly binds to HA monomers
present in HA trimer-depleted samples, though less strongly than
to HA trimers.
We extended these findings by examining the staining pattern of
several StRAbs including human 2A06, 2G02, and 3A01, in
addition to C179 and 1F02, on fixed and permeabilized MDCK
cells 5 h post-IAV PR8 infection. Cells were infected in the
presence of monensin, which greatly slows trafficking through the
GC, to simplify the staining pattern, since we were essentially
interested in the ability of the StRAbs to stain ER (HA monomers)
vs. post-ER (HA trimers) compartments [14]. Cells were simulta-
neously stained with rabbit anti-IAV neuraminidase (NA) pAbs
that localize NA throughout the entire secretory pathway. 1F02
(Fig. 1, B–G), 2G02 (Fig. 1, H–M), and other human StRAbs
tested (Fig. S3) clearly recognize HA in both ER and GC,
consistent with binding HA monomers and trimers, respectively.
C179 (Fig. S3, A–F) binds trimerized HA in the GC and exhibits
weak binding to HA monomers in the ER, consistent with the
biochemical findings.
To further analyze the interaction of StRAbs with monomeric
vs. trimerized HA, we developed a novel IF-based method to
determine Ab avidity for HA in progressive stages of its biogenesis
in IAV PR8-infected cells. This assay measures the Ab concen-
tration required to give half-maximal staining of HA in various
compartments by IF of fixed and permeabilized cells, exploiting
the exclusive localization of HA monomers and trimers to ER vs.
GC, respectively. We validated this method using H28-E23, a
well-known anti-HA head mAb that binds monomeric and
trimerized HA with similar avidity [9,14] (Fig. 1N). Our data
clearly demonstrate that human StRAbs also bind HA monomers
and trimers with similar avidity (Fig. 1N). Note that the calculated
avidity of all Abs examined is lower than the values obtained by
ELISA (described below), what is probably related to the
unavoidable effect of paraformaldehyde modification of Lys
residues, commonly present on the HA surface.
Based on these findings, we conclude that StRAb epitopes are
generated rapidly during the biogenesis of HA and are present on
monomeric HA in a conformation that is highly similar to that
present on trimerized HA.
Processing of HA Glycans in the Distal Golgi Complex
Impairs StRAb Binding
As previously observed [9,14,31], [35S]-Met pulse-labeled HA
recovered by HA trimer- or HA monomer/trimer-specific mAbs
(H17-L2 or H28-E23, respectively) demonstrates an initial slight
increase in mobility in SDS-PAGE due to trimming of N-linked
oligosaccharides in the early GC followed by a gradual decrease in
mobility with further glycan modification in the distal GC (Fig. 2A).
Remarkably, both mouse C179 and human 1F02 exhibited a
greatly reduced ability to recover slowly migrating HA generated
in the distal GC (Fig. 2B). Similar results were obtained using
additional human StRAbs (2A06, 2G02, and 3A01; Fig. S1) or
when examining 1F02 binding to HAs from a panel of drifted
human IAV H1N1 strains (Fig. S2).
We extended this finding using StRAbs to deplete HA from
[35S]-Met pulse-chased cell lysates. While H28-E23 completely
depleted all HA species, as expected, 1F02 and particularly C179
failed to remove HA with mature N-linked glycans (Fig. 2C).
Author Summary
Extensive variation in the IAV HA globular domain severely
impedes influenza vaccination. Recent findings demon-
strate that StRAbs, specific Abs to the highly conserved
stem region of HA, can protect hosts against a broad
variety of influenza virus strains. In investigating the
binding of StRAbs to HA during its biogenesis in IAV-
infected cells, we find that these Abs can bind HA
monomers prior to their trimerization in the GC. Binding
to HA becomes temperature-dependent, however, as N-
linked oligosaccharides mature during transport of trimer-
ized HA through the GC to the cell surface. Our findings
support the potential use of monomeric HA stem
immunogens to induce broadly neutralizing Abs, but raise
the possibility of eventual viral escape from StRAbs, based
on structural alterations in the HA that increase steric
hindrance of HA stem N-linked glycans on StRAb binding.
Biogenesis of the HA Stem
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If the loss of StRAb binding is due to HA N-linked
oligosaccharide modifications in the distal GC, preventing N-
linked glycosylation or blocking N-linked glycan processing should
enable StRAbs to bind HA throughout a long chase. Treatment of
IAV PR8-infected cells with tunicamycin to prevent N-linked
glycosylation (Fig. 3A) or a mixture of 1-deoxymannojirimycin
(DMN) and swainsonine (SWN) to inhibit Golgi a-mannosidases I
and II, respectively (Fig. 3B), completely blocked the mobility shift
associated with N-linked oligosaccharide processing and enabled
C179 and 1F02 (Fig. 3, A and B) as well as 2A06, 2G02, and 3A01
(Fig. S4) to maintain binding to HA 20 min post-[35S]-Met pulse.
In line with the experiments described above, StRAbs nearly
Figure 1. Identification of HA species recognized by StRAbs. (A) IAV PR8-infected MDCK cells were labeled with [35S]-Met and chased at 37uC.
Detergent cell lysates were treated with an irrelevant mAb (10G-4 to the VSV N protein; no depletion) or depleted of HA monomers (mHA depleted)
or HA trimers (tHA depleted) using the anti-HA head mAbs Y8-10C2 or H17-L2, respectively, at 4uC. Cell extracts were then incubated with the StRAbs
C179 or 1F02 also at 4uC in a second round of immunoprecipitation (IP). Collected HA species were analyzed by non-reducing SDS-PAGE and
fluorography. (B–M) MDCK cells were infected with IAV PR8 in the absence (no treatment) or presence of 10 mM monensin. Cells were fixed,
permeabilized, and incubated with the human StRAbs 1F02 (B–G) and 2G02 (H–M) (green channel) and rabbit pAbs to NA (red channel). DNA was
labeled using DAPI (blue channel). Stained cells were examined by fluorescence confocal microscopy. Bars: 10 mm. Arrowheads point NA co-localizing
with HA monomers in the nuclear envelope (ER). (N) MDCK cells were infected with IAV PR8 in the presence of 10 mM monensin and processed for IF
confocal microscopy using 2-fold serial dilutions of the purified anti-HA head mAb H28-E23 (control) or the StRAbs 1F02 and 2G02. Fluorescence
intensities of the ER (HA monomers) and GC (HA trimers) are expressed as arbitrary units (a.u.). Data are represented as mean6 SEM from,100 cells/
Ab dilution.
doi:10.1371/journal.ppat.1004204.g001
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(C179) or fully (1F02) depleted all forms of HA present in
radioactive lysates from cells treated with Golgi a-mannosidases
inhibitors (Fig. 3C; compare with Fig. 2C).
Crystal structures of StRAbs bound to HA reveal that N-linked
oligosaccharides tightly ring the Ab (Fig. 4A shows mouse Fab
C179 binding to an H2 HA [32]; human StRAbs bind HA
similarly [21,30,33,34]; Fig. 4B shows the IAV PR8 HA used in
this study for comparison only [35]), consistent with the idea that
addition of saccharide subunits in the GC increases the steric
hindrance sufficiently to decrease the StRAb binding avidity. This
predicts that smaller ligands will not be affected by GC N-linked
oligosaccharide modifications. We confirmed this prediction using
HB80.4, a tiny (65 residues), computationally designed protein
that binds to the same region of the HA stem as StRAbs with nM
avidity (HB80.4 binding to an H1 HA is shown in Fig. 4C [36]).
Unlike the StRAbs used in this study, HB80.4 bound all HA
species in radioactive pulse-chase experiments (Fig. 4D), including
HAs from a panel of drifted human IAV H1N1 strains (Fig. S5).
All together, these findings demonstrate first, that StRAbs bind
to the HA stem independently of N-linked glycosylation and
second, that modification of HA glycans, presumably those located
in the proximity of the StRAb epitopes, interferes with StRAb
binding to HA under the conditions we have employed.
StRAb Binding to Virus-Derived HA Is Temperature-
Sensitive
Our results predict that StRAbs should bind poorly to virion
HA, due to the presence of mature N-linked oligosaccharides. To
test this, we purified IAV PR8 from MDCK cell supernatants,
collected HA from Triton X-100 lysates with anti-HA head (H17-
L2 and H28-E23) or anti-HA stem (C179 and 1F02) mAbs, and
measured bound HA by immunoblotting (IB) using the mAb CM-
1 (specific for a linear epitope in HA1) [14]. While H17-L2 and
H28-E23 efficiently recovered mature (N-linked glycan-processed)
HA from IAV PR8-infected cell lysates (Fig. 5A) and viral HA
(Fig. 5B), neither C179 nor 1F02 detectably bound cell-derived
mature HA (Fig. 5A) or viral HA (Fig. 5B) under these conditions.
In line with our previous observations, StRAbs only reacted with
non-processed HA species present in detergent lysates made from
cells infected with IAV PR8 (Fig. 5A).
Figure 2. Processing of HA glycans in the distal Golgi complex shields HA from StRAb binding. (A and B) IAV PR8-infected MDCK cells
were pulse-labeled with [35S]-Met and chased at 37uC. At the end of each chase time point cells were detergent-lysed and then subjected to IP with
the anti-HA head mAbs H17-L2 and H28-E23 (A) or the StRAbs C179 and 1F02 (B) at 4uC. Immunocollected HA species were analyzed by non-reducing
SDS-PAGE and fluorography. pHA: processed, glycosylated HA. (C) Detergent extracts from [35S]-Met-labeled and chased MDCK cells infected with IAV
PR8 were treated with an irrelevant mAb (10G-4 to the VSV N protein; no depletion) or HA-depleted with the mAbs H28-E23 (control), C179, and 1F02
at 4uC as described in Fig. 1A before being incubated with H17-L2 also at 4uC in a second round of IP. Precipitated HA species were visualized by SDS-
PAGE under non-reducing conditions and fluorography.
doi:10.1371/journal.ppat.1004204.g002
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Figure 3. Inhibition of N-linked glycosylation or N-linked oligosaccharide processing restores proper StRAb binding to HA. (A–C)
MDCK cells infected with IAV PR8 were treated with tunicamycin (A) or a mixture of DMN and SWN (B and C) for 30 min before being labeled with
[35S]-Met and chased in continuous presence of the inhibitors at 37uC. (A and B) Detergent cell extracts were subjected to IP using the anti-HA head
mAbs H17-L2 and H28-E23 or the StRAbs C179 and 1F02 at 4uC. Immunocollected proteins were resolved by non-reducing SDS-PAGE and visualized
by fluorography. n-gHA: non-glycosylated HA; n-pHA: non-processed, glycosylated HA. (C) Detergent cell lysates were incubated with an irrelevant
mAb (10G-4 to the VSV N protein; no depletion) or HA-depleted with the mAbs H28-E23 (control), C179, and 1F02 at 4uC before being treated with
H17-L2 also at 4uC in a second round of IP as described in Fig. 2C. Precipitated HA species were analyzed by non-reducing SDS-PAGE and
fluorography.
doi:10.1371/journal.ppat.1004204.g003
Biogenesis of the HA Stem
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These findings are at odds with the biological activity exerted by
C179, 1F02, and other StRAbs in virus neutralization and
protection experiments. Until this point, in all of the experiments
shown, we incubated Abs with HA at 4uC, a precaution typical for
biochemical work (low temperature limits the activity of proteases
and other enzymes). Abs do not physiologically function at 4uC:
neutralization assays in vitro are typically performed at 37uC, and in
vivo means 37uC in non-febrile humans, and several degrees higher
in mice, birds, and febrile patients.
Indeed, we previously showed that Y8-10C2, a mAb absolutely
specific to HA monomers at 4uC, binds HA trimers at 37uC due to
the increased flexibility of the HA globular domains that enable
Ab access to its epitope at the trimer interface [37]. Could a
similar phenomenon apply to StRAbs? Incubation of StRAbs with
IAV PR8-infected cell lysates or detergent lysates from purified
virus at 37uC resulted in the recovery of similar amounts of cell-
derived mature HA (Fig. 5A) or viral HA (Fig. 5B) as observed
with HA head-specific mAbs. We further observed temperature-
dependent binding of the human StRAbs 1F02 and 2G02 in
ELISA using whole IAV PR8 as antigen, while the anti-HA head
mAb H28-E23 bound IAV PR8 in a temperature-independent
manner, as expected (Fig. 5C).
The accessibility of the StRAb epitope at 37uC might be related
to the mobility of the oligomerized HA stem domains relative to
each other, as required for the binding of Y8-10C2 to its epitope
on trimerized HA [37]. To assess this possibility, we cross-linked
HA present in detergent extracts from IAV PR8-infected cells or
purified virus with the non-cleavable cross-linker dimethyl
pimelimidate (DMP) before being incubated at 37uC with the
mouse StRAb C179. We analyzed bound HA via reducing SDS-
PAGE and IB using a mixture of CM-1 and the denatured HA-
specific, anti-HA2 mAb RA5-22 [14]. Under these conditions, HA
Figure 4. Steric hindrance due to N-linked glycan processing shields HA from StRAb binding. (A–C) PyMOL images of the crystal
structures of mouse Fab C179 in complex with the IAV A/Japan/305/57 (H2N2) HA monomer [RSCB protein database entry: 4HLZ) [32] (A)]; the IAV
PR8 HA monomer used in this study [shown for comparison only; RSCB protein database entry: 1RVX) [35] (B)]; and HB80.4 in complex with the IAV A/
Brevig Mission/1/18 (H1N1) HA monomer [RSCB protein database entry: 4EEF) [36] (C)], showing glycosylation-prone Asn residues within or around of
the stem region of HA (red; H3 numbering scheme). The HA1 and HA2 peptides are displayed in purple and pink, respectively. (D) Detergent extracts
from [35S]-Met-labeled and chased IAV PR8-infected MDCK cells at 37uC were treated with an irrelevant mAb (10G-4 to the VSV N protein; no
depletion) or depleted of HA monomers (mHA depleted) or HA trimers (tHA depleted) using the anti-HA head mAbs Y8-10C2 or H17-L2, respectively,
at 4uC as described in Fig. 1A. Detergent cell lysates were then incubated with 2.4 mg/ml FLAG-tagged HB80.4 also at 4uC. HA species in complex with
HB80.4 were immunocollected with the anti-FLAG mAb M2 at 4uC and analyzed by non-reducing SDS-PAGE and fluorography. pHA: processed,
glycosylated HA.
doi:10.1371/journal.ppat.1004204.g004
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oligomers completely dissociate and unfold [14]. However, DMP-
mediated cross-linking of HA reduced its dissociation in a
concentration-dependent manner as seen by decreasing amount
of HA monomers and increasing amounts of HA oligomers
(Fig. 5D). Importantly, with increasing concentrations of cross-
linker the amount of C179-reactive HA remains relatively constant
Figure 5. Temperature-dependent StRAb binding to cell-derived mature HA or viral HA. (A and B) IAV PR8-infected MDCK cells (A) or
purified IAV PR8 (B) were detergent-lysed and incubated with an irrelevant mAb (HB-65 to the IAV NP protein; negative control), the anti-HA head
mAbs H17-L2 and H28-E23, or the StRAbs C179 and 1F02 at 4uC or 37uC. Precipitated HA species were resolved by non-reducing SDS-PAGE and
visualized by IB using the denatured HA-specific, anti-HA1 mAb CM-1. pHA: processed, glycosylated HA; vHA: viral HA. (C) ELISA plates coated with
egg-grown IAV PR8 were treated with the mouse anti-HA head mAb H28-E23 (control) or the human StRAbs 1F02 and 2G02 at 4uC or 37uC, followed
by primary Ab detection using HRP-conjugated anti-mouse or anti-human Abs, respectively. Optical density (OD) values are expressed as arbitrary
units (a.u.). Data are represented as mean 6 SEM from one experiment done in duplicate and repeated at least three times with similar results. (D)
Detergent cell or viral lysates were cross-linked with increasing amounts of DMP. After addition of an excess of Tris-HCl to quench the reaction, cross-
linked lysates were incubated with the StRAb C179 at 37uC. Immunocollected proteins were analyzed by SDS-PAGE under reducing conditions and IB
using CM-1 and the denatured HA-specific, anti-HA2 mAb RA5-22. Asterisk: non-specific band. (E) Recombinant HA trimers (IAV PR8-foldon-His6
recHA; recHA3) purified from insect cells were resuspended in 1% Triton X-100 and subjected to 4uC or 37uC IP as described in A and B. Precipitated
recHA3 was visualized by non-reducing SDS-PAGE and IB using CM-1.
doi:10.1371/journal.ppat.1004204.g005
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(Fig. 5D). This strongly implies that the temperature-dependent
reactivity of StRAbs to HA relies on the enhanced flexibility of
complex N-linked glycans rather than the HA polypeptide itself.
Taken together, these findings demonstrate that StRAb binding
to HA exhibits a unique sensitivity to N-linked oligosaccharide
structures that is highly dependent on temperature.
Recombinant HA: When a Liability Becomes an Asset
The ability to generate large amounts of native HA from
cultured insect cells is a boon for both basic science and vaccine
development. One of the theoretical limitations of this system is
the limited capacity of insect cells to generate complex N-linked
glycans. Our findings predict, however, that the failure to modify
simple N-linked oligosaccharides will enhance, and not limit HA
stem antigenicity/immunogenicity.
Indeed, using HA trimers purified from insect cells [38] in a
highly native state [14] we found that binding of StRAbs occurs
perfectly well at 4uC (Fig. 5E), as measured under the same
conditions used in Fig. 5, A and B. Thus, antigenicity of the HA
stem is fortuitously enhanced by a failure of the producer cell to
faithfully recapitulate the biogenesis of HA in vivo.
Discussion
Although many questions remain to be answered, there is a
tremendous enthusiasm regarding the potential of StRAbs to
improve IAV vaccination. At the very least, StRAbs should be
useful therapeutically in severe influenza. At the very most,
vaccines that effectively induce StRAbs could provide long lasting
protection and greatly diminish the annual toll of seasonal IAV
and prevent pandemics arising from introduction of novel HA
subtypes into the human population from the enormous animal
reservoir [39,40].
Effectively inducing StRAbs requires more detailed knowledge
of the B cell response to HA. It is generally believed that the
greater intrinsic immunogenicity of the HA globular domain
suppresses Ab responses to the HA stem. This remains to be
established experimentally, however, and it will be of interest
whether this is due strictly to an enhanced ability of anti-HA head
B cells to compete for limiting amounts of HA in primary and
secondary immune responses. If this is the case, then there are
several potential strategies to boost HA stem immunogenicity.
First, the immunogenicity of the HA globular domain can
potentially be minimized by engineering HA to contain a maximal
number of N-linked oligosaccharides to shield the antigenic
regions. The H1 and H3 HAs demonstrated a clear tendency to
increase the numbers of N-linked glycans in the head [41,42],
suggesting that this might be possible. In line with this hypothesis,
Eggink and colleagues recently designed an HA with a hyper-
glycosylated globular domain that greatly increases the mouse
broadly neutralizing StRAb response [43].
Second, vaccines could be formulated with high avidity Abs
(natural or particularly designed Abs like HB80.4) specific for the
HA head to block activation of B cells specific for this region. A
natural, much cheaper, and probably more effective alternative
method is to simply immunize individuals with vaccines to prior
IAV strains to which they already possess high anti-HA globular
domain Ab titers. A related strategy is to exploit the original
antigenic sin [44], i.e. the ability of secondary B cells to
immunodominate primary B cells, and immunize with vaccines
containing HA with a completely novel head and a conserved stem
region [45–47]. This requires, however, that individuals already
possess a sufficient number of secondary B cells making StRAbs, so
it cannot be used for children receiving their first IAV vaccine.
Indeed, it may be critical to focus on truly naı¨ve individuals, since
true to its name, original antigenic sin may increase the difficulty
of inducing effective StRAb responses in individuals with
immunodominant Ab responses specific for the globular domain.
Third, the stem region of HA alone could be used as a vaccine
immunogen. Protective StRAbs are highly dependent on HA
conformation, as indicated by their inability to bind acid-triggered
HA or denatured HA in IBs [30]. Generating folded HA stem-
only immunogens could be difficult, particularly if StRAb binding
requires HA oligomerization, as concluded by Krammer and
colleagues [48] studying soluble HA produced by insect cells. By
contrast, using a novel, widely applicable IF-based method to
measure Ab avidity for antigens in situ (in this case, fixed and
permeabilized IAV-infected cells), we found that all human
StRAbs we tested bind HA monomers with nM avidity (although
in the case of mouse C179 with clearly diminished avidity) (Figs. 1,
S1, S2, and S3). Krammer et al.’s failure to detect StRAb binding
to monomeric HA could be related to the absence of the COOH-
terminal residues in the recombinant HAs used [48], but in any
event, it shows the importance of carefully characterizing the
antigenicity of recombinant vaccine constructs. Our findings
support the concept of inducing StRAbs with recombinant HA
monomers, obviating the need for complex trimerization/foldon
domains. While the engineering of immunogenic HA stem-only
immunogens is challenging [26], Bommakanti and colleagues
[49,50] describe rationally designed trimerized HA stem-only
constructs that bound and induced neutralizing StRAbs. In
deploying such vaccines it is essential to be cognizant of the
possible deleterious effects of immunogens that enhance pathoge-
nicity, as recently reported by Khurana et al. [51]. Though this
phenomenon to date is limited to the swine model [51], a similar
phenomenon might account for Ab-enhanced human disease with
recently shifted viruses [52].
One of our most interesting findings is the temperature
dependence of StRAb binding to mature HA (Fig. 5). Mammals
evolved to carefully control their temperatures, and Ab binding at
4uC is clearly irrelevant to StRAb function in vivo. This is not,
however, germane to the major conclusions of our study. Rather,
our findings provide novel mechanistic details regarding the
participation of N-linked oligosaccharides in the thermodynamics
of the StRAb-HA interaction. To our knowledge, this is only the
second example of temperature-dependent neutralizing Ab
binding to IAV HA, the first being our 1993 study where we
reported the temperature-dependent binding of Y8-10C2, a mAb
specific for the HA Sa antigenic site [37], to HA trimers. Y8-10C2
temperature dependence is based on the ‘‘breathing’’ of the HA
globular domains to enable Ab access to its epitope, which is
sterically blocked by the close proximity of neighboring monomers
in trimerized HA in its minimal energy state. The effect of the
temperature-dependent conformational breathing on binding of
neutralizing Abs to viruses is now a topic of great interest and
immediately relevant to HIV-1 and flavivirus vaccine development
[53,54].
The temperature dependence of StRAb binding to HA is likely
due not to the conformational gyrations of the HA polypeptide per
se, but rather to the flexibility of the N-linked oligosaccharides that
surround the StRAb-binding region, since chemical cross-linking
of HA trimers to limit polypeptide flexibility does not alter the
temperature-dependent StRAb binding to HA (Fig. 5). Thus,
HB80.4, a small-engineered protein ligand with a very similar
binding footprint, binds in a temperature-independent manner
(Figs. 4 and S5). This observation demonstrates the potential
superiority of tiny, computationally designed Abs that are not
subject to glycan mediated interference, almost certainly due to
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their small size. Most directly, StRAb-temperature dependence is
abrogated by either preventing HA glycosylation with tunicamycin
or HA glycan maturation with Golgi a-mannosidases inhibitors in
mammalian cells (Figs. 3 and S4), or by expressing HA in insect
cells (Fig. 5), which typically do not generate complex N-linked
oligosaccharides [55].
Wang and colleagues [56] and more recently Chen et al. [57]
engineered a recombinant HA carrying simple sugars at each
glycosylation site that, used as vaccine, elicits enhanced cross-strain
neutralization and protection in mice and ferrets. Thus, our
findings have also important practical impact, since they provide
basic information that explains the improved ability of HA with
simple N-linked oligosaccharides to elicit StRAbs and provide
broader immunity to drifted and shifted HAs [56,57], what is
consistent with a temperature-dependent glycan steric hindrance
of StRAb binding to mature and viral HA.
If StRAb binding to HA is so precarious, could effective large-
scale HA stem vaccination in humans generate sufficient immune
pressure to arise HA stem escape variants? Given the high
conservation of N-linked oligosaccharide sites in the stem region of
HA [41], the fitness costs of adding a new site in the StRAb
footprint are likely to be sufficiently severe to preclude this escape
strategy. On the other hand, amino acid substitutions in or around
of the HA stem could re-orient the existing N-linked glycans to
increase their steric blockade effect, since examination of the
crystal structures of StRAbs bound to HA reveals a close tolerance
between the Ab and several N-linked oligosaccharides located in
the HA stem (Fig. 4). Reported difficulties in generating StRAb-
escape mutants in vitro [21,27,30] strongly suggests that viral
escape requires changing multiple residues, either to attain escape
itself or to regain fitness lost from altering the amino acid(s)
required for escape. Compensatory mutations could be also
located at a considerable distance from the HA stem epitope, as
shown by Wang and colleagues [58]. In this unique example of
StRAb viral escape to date, a point mutation on an IAV H1N1
HA, L415I, distant from any known StRAb antigenic site,
presumably induces a conformational change on the HA stem
domain in order to fit the bulkier side chain of Ile [58]. Likewise,
the isolation of Y8-10C2 escape mutants revealed that the stem
region of HA controls the Ab accessibility to its epitope in the Sa
site at the HA trimer interface [37].
Although viral escape from StRAbs is likely to be difficult, our
findings suggest that given enough time and immune pressure,
escape via a conformational mechanism is a real possibility. These
are not necessarily unmitigated bad news, however, since
mutations may compromise the HA function sufficiently to reduce
viral pathogenicity or transmissibility.
Materials and Methods
Cells
MDCK cells (American Type Culture Collection; Manassas,
VA) were maintained in complete medium (Dulbecco’s modified
Eagle’s medium+GlutaMAX-I (Gibco; Grand Island, NY), sup-
plemented with 4.5 mg/ml D-glucose, 110 mg/ml sodium pyru-
vate, and 7.5% heat-inactivated fetal bovine serum) at 37uC in a
humidified atmosphere of 9% carbon dioxide in air.
Virus and Viral Infections
IAV PR8 was grown in the allantoic cavity of embryonated
chicken eggs and conserved as infectious allantoic fluid at 280uC.
MDCK monolayers were washed twice with Dulbecco’s phos-
phate-buffered saline (DPBS; Gibco) and incubated with AIM
medium (Minimum essential medium+GlutaMAX-I, supplement-
ed with Earle’s salts, 0.1% bovine serum albumin, and 20 mM
Hepes pH 6.6) containing 10 infectious doses per cell of egg-grown
IAV PR8 at 37uC in a humidified atmosphere of 9% carbon
dioxide in air. After 1 h, the infection medium was replaced by
complete medium and incubation continued for additional 4 h.
Infection of MDCK cells with IAV A/Fort Monmouth/1/47, A/
Denver/1/57, A/New Caledonia/20/99, or A/California/7/09
was carried out for 17 h under the same culture conditions.
Purification of IAV PR8 from Mammalian Cell
Supernatants
Confluent monolayers of MDCK cells growing in 175 cm2
culture flasks (Thermo Scientific Nunc; Rochester, NY) were
extensively washed with DPBS and infected with 1 infectious dose
per cell of egg-grown IAV PR8 in TCID50 medium (Minimum
essential medium+GlutaMAX-I, supplemented with 1 mM Hepes
pH 7.5, 1 mg/ml trypsin TPCK-treated (Worthington; Lakewood,
NJ), and 50 mg/ml gentamycin) for three days at 37uC in a
humidified atmosphere of 9% carbon dioxide in air. Cell
supernatants were layered on the top of a 20% (w/v) sucrose
cushion and ultracentrifuged in a SW38 rotor (Beckman Coulter
Inc.; Fullerton, CA) for 4 h at 24,0006g, 4uC. The viral pellet was
resuspended in DPBS supplemented with calcium and magnesium
(DPBS-Ca/Mg; Gibco), re-layered the on top of a 15–60% (w/v)
sucrose gradient, and ultracentrifuged in a SW41 rotor (Beckman
Coulter Inc.) for 2 h at 35,0006 g, 4uC. Purified IAV PR8 were
collected from between the 15% and 60% sucrose interface,
ultracentrifuged again to clear residual sucrose, and resuspended
in DPBS-Ca/Mg. Viral stocks were stored at 4uC.
Antibodies
The mouse StRAb C179 was purchased from Takara Bio, Inc.-
Clontech (Mountain View, CA). All human StRAbs used in this
study were described in previous publications [23,28]. Mouse
mAbs Y8-10C2, H17-L2, and H28-E23 to the HA globular
domain, HB-65 to the NP protein, and 10G-4 to the VSV N
protein, as well as rabbit anti-NA pAbs were reported elsewhere
[9,59–61]. FLAG-tagged HB80.4 was described previously [36].
The mouse anti-FLAG mAb M2 was from Sigma-Aldrich (Saint
Louis, MO). DyLight 488-conjugated donkey anti-mouse IgG,
Alexa Fluor 488-conjugated donkey anti-human IgG, and Dy-
Light 546-conjugated donkey anti-rabbit IgG were from Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA). The HRP-
conjugated anti-mouse IgG TrueBlot ULTRA was obtained from
eBioscience (San Diego, CA).
Radioactive Pulse-Chase Analysis, Immunoprecipitation,
and Immunoblotting
Equivalent amounts of IAV PR8-infected MDCK cells were
pulse-labeled for 2 min with [35S]-Met (PerkinElmer; Waltham,
MA) at 37uC, chased at the same temperature, detergent lysed,
and subjected to IP as described [14]. When indicated,
tunicamycin (5 mg/ml) or a mixture of DMN (1 mM) and SWN
(10 mM) (Calbiochem; Billerica, MA) were added to cells 30 min
before radiolabeling and maintained throughout the radioactive
pulse and chase periods. Immunocollected proteins were analyzed
by SDS-PAGE and visualized by exposing dried gels to Care-
stream Kodak BioMax MR (Sigma-Aldrich) films. Gels were
stained with Coomassie brilliant blue R (MP Biomedicals, LLC;
Santa Ana, CA) prior to drying to ensure that the Abs were equally
recovered and loaded in all lanes. Since equal amounts of IgG
were added to each sample, this served as a loading control. IB
studies were carried out as reported [62].
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Immunofluorescence Confocal Microscopy
MDCK cells growing on cover glasses (Marienfeld GmbH &
Co.KG; Lauda-Ko¨nigshofen, Germany) were infected with IAV
PR8 in the absence or presence of 10 mM monensin (Sigma-
Aldrich) and prepared for IF confocal microscopy as described
previously [14]. Inverted coverslips were mounted on microscope
slides using Fluoromount G with DAPI (Electron Microscopy
Sciences; Hatfield, PA) and examined with a TCS SP5 (DMI
6000) confocal microscope system (Leica Microsystems; Deerfield,
IL).
Antibody Binding Analysis by Immunofluorescence
Confocal Microscopy
MDCK cells were infected with IAV PR8 in the presence of
10 mM monensin and processed for IF confocal microscopy using
2-fold serial dilutions of purified mAbs (from 500 nM to 0.05 nM).
,100 cells/Ab dilution were imaged using the same microscope
and image acquisition settings. Fluorescence intensities of HA
monomers in the ER and HA trimers in the GC were measured
on background-subtracted images using the ImageJ software
(http://rsbweb.nih.gov/ij). Ab Kd values were then calculated
with the Prism 6 software (GraphPad; La Jolla, CA) by fitting the
hyperbola directly to the saturation isotherm by non-linear
regression.
Chemical Cross-linking
IAV PR8-infected MDCK cells or purified IAV PR8 were
washed twice with DPBS and lysed with ice-cold lysis buffer (0.5%
Triton X-100, 200 mM triethanolamine pH 8, 150 mM NaCl,
and 5 mM EDTA) supplemented with the complete, Mini,
EDTA-free protease inhibitor cocktail (Roche Diagnostics, Indi-
anapolis, IN). Equivalent amounts of detergent lysates were
incubated with increasing amounts (0, 0.05, 0.1, 0.25, and
0.5 mg/ml) of the cross-linker DMP (Thermo Scientific Pierce;
Rockford, IL) for 3 h at room temperature. The reaction was
stopped by adding 50 mM Tris-HCl pH 7.5 to each sample.
ELISA
96-well ELISA plates (Greiner Bio-One; Monroe, NC) were
prepared by adding 100,000 TCID50 egg-grown IAV PR8 diluted
in DPBS to each well. After overnight incubation at 4uC, plates
were washed three times with DPBS+0.05% Tween-20, and pre-
cooled on ice prior to Ab addition. Abs were incubated on plates
for 2 h at 4uC or 37uC. After extensively washing with DPBS+
0.05% Tween-20, bound primary Abs were detected by incubat-
ing plates with HRP-conjugated rat anti-mouse IgG kappa light
chain (H28-E23) or goat anti-human IgG kappa light chain (1F02
and 2G02) (SouthernBiotech; Birmingham, Al) for 1 h at 4uC.
ELISA plates were washed again with DPBS+0.05% Tween-20
and incubated with the SureBlue TMB Microwell Peroxidase
Substrate (KPL; Gaithersburg, MD) for 5 min at room temper-
ature. The reaction was stopped by adding 1 M HCl to each
sample. The ODs were determined at 450 nm on a Spectra Max
M5 microplate reader (Molecular Devices; Downington, PA) and
the Ab Kd values were then calculated using the Prism 6 software.
Supporting Information
Figure S1 Binding of additional human StRAbs to
monomeric HA and non-processed HA trimers. IAV
PR8-infected MDCK cells were labeled with [35S]-Met and
chased at 37uC. Detergent cell extracts were incubated with the
HA monomer/trimer-specific, anti-HA head mAb H28-E23
(control) or the StRAbs 2A06, 2G02, and 3A01 at 4uC.
Immunocollected HA species were visualized by non-reducing
SDS-PAGE and fluorography. pHA: processed, glycosylated HA.
(TIF)
Figure S2 StRAbs recognize HA monomers and non-
processed, trimerized HA from additional drifted hu-
man IAV H1N1 strains. MDCK cells infected with IAV A/
Fort Monmouth/1/47, A/Denver/1/57, A/New Caledonia/20/
99, or A/California/7/09 were [35S]-Met pulse-labeled and
chased at 37uC before being detergent-lysed. HA species were
precipitated with the StRAb 1F02 at 4uC and then analyzed by
non-reducing SDS-PAGE and fluorography.
(TIF)
Figure S3 Reactivity of additional StRAbs to HA mono-
mers and trimers assayed by immunofluorescence
confocal microscopy. (A–R) MDCK cells were infected with
IAV PR8 in the absence (no treatment) or presence of 10 mM
monensin as described in Fig. 1, B–M. HA was labeled on fixed
and permeabilized cells using the mouse StRAb C179 (A–F) or the
human StRAbs 2A06 (G–L) and 3A01 (M–R) (green channel). NA
was detected using rabbit pAbs (red channel). DNA was visualized
using DAPI (blue channel). Stained cells were examined by
fluorescence confocal microscopy. Bars: 10 mm. Arrowheads point
NA co-localizing with HA monomers in the nuclear envelope
(ER).
(TIF)
Figure S4 Inhibition of N-linked glycan processing
allows proper StRAb binding to HA. IAV PR8-infected
MDCK cells were treated with a mixture of DMN and SWN
before being pulse-labeled with [35S]-Met and chased at 37uC in
the continuous presence of the inhibitors as described in Fig. 3, B
and C. Detergent cell extracts were incubated with the anti-HA
head mAb H28-E23 (control) or the StRAbs 2A06, 2G02, and
3A01 at 4uC. Immunocollected proteins were resolved by SDS-
PAGE under non-reducing conditions and visualized by fluorog-
raphy. n-pHA: non-processed, glycosylated HA.
(TIF)
Figure S5 HB80.4 overcomes N-linked oligosaccharide
shielding within the stem region of HAs from additional
drifted human IAV H1N1 strains. MDCK cells infected with
IAV A/Fort Monmouth/1/47, A/Denver/1/57, A/New Cale-
donia/20/99, or A/California/7/09 were labeled with [35S]-Met
and chased at 37uC. Detergent cell lysates were incubated with
FLAG-tagged HB80.4 at 4uC. HA species in complex with
HB80.4 were precipitated with the anti-FLAG mAb M2 also at
4uC and then analyzed by non-reducing SDS-PAGE and
fluorography. Asterisk: non-specific band; pHA: processed,
glycosylated HA.
(TIF)
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